Susceptibility to experimental autoimmune encephalomyelitis is associated with altered B-cell subsets distribution and decreased serum BAFF levels

Immunology Letters

Volumn 135, Issue 1-2, 2011, Pages 108-117

  Lee Chang, Catalina ^a   Lefranc, Didier ^a   Salleron, Julia ^b   Faveeuw, Christelle ^a   Allet, Cecile ^c   Vermersch, Patrick ^a   Oxombre, Bénédicte ^a   Prin, Lionel ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

B cell activating factor belonging to the TNF family; B1a B cells; Experimental autoimmune encephalomyelitis; Marginal zone B cells; Regulatory B cells; Transitional 2 B cells

Indexed keywords

B CELL ACTIVATING FACTOR; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; HOMEOSTASIS; IMMUNOPATHOGENESIS; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; DISEASE SUSCEPTIBILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MULTIPLE SCLEROSIS;

EID: 78751705050     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.10.006     Document Type: Article

References (66)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
2. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009, 65:499-509.
3. Jäger A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009, 183:7169-7177.
4. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008, 14:337-342.
5. Pachner A.R., Brady J., Narayan K. Antibody-secreting cells in the central nervous system in an animal model of MS: phenotype, association with disability, and in vitro production of antibody. J Neuroimmunol 2007, 190:112-120.
6. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999, 5:170-175.
7. Harp C.T., Lovett-Racke A.E., Racke M.K., Frohman E.M., Monson N.L. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol 2008, 128:382-391.
8. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000, 1:475-482.
9. Cyster J.G. Lymphoid organ development and cell migration. Immunol Rev 2003, 195:5-14.
10. Endres R., Alimzhanov M.B., Plitz T., Fütterer A., Kosco-Vilbois M.H., Nedospasov S.A., et al. Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells. J Exp Med 1999, 189:159-168.
11. Fu Y.X., Huang G., Wang Y., Chaplin D.D. B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med 1998, 187:1009-1018.
12. Lefranc D., Almeras L., Dubucquoi S., de Seze J., Vermersch P., Prin L. Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. J Immunol 2004, 172:669-678.
13. Zephir H., Almeras L., El Behi M., Dussart P., de Seze J., Steibel J., et al. Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. J Neuroimmunol 2006, 179:53-64.
14. El Behi M., Zéphir H., Lefranc D., Dutoit V., Dussart P., Devos P., et al. Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs. J Neuroimmunol 2007, 182:80-88.
15. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
16. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
17. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
18. Mann M.K., Maresz K., Shriver L.P., Tan Y., Dittel B.N. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007, 178:3447-3456.
19. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
20. Duan B., Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006, 5:403-408.
21. Lopes-Carvalho T., Foote J., Kearney J.F. Marginal zone B cells in lymphocyte activation and regulation. Curr Opin Immunol 2005, 17:244-250.
22. Kroese F.G., Butcher E.C., Stall A.M., Herzenberg L.A. A major peritoneal reservoir of precursors for intestinal IgA plasma cells. Immunol Invest 1989, 18:47-58.
23. Brummel R., Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005, 174:2429-2434.
24. Oliver A.M., Martin F., Gartland G.L., Carter R.H., Kearney J.F. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 1997, 27:2366-2374.
25. Allman D., Lindsley R.C., DeMuth W., Rudd K., Shinton S.A., Hardy R.R. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001, 167:6834-6840.
26. Su T.T., Guo B., Wei B., Braun J., Rawlings D.J. Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev 2004, 197:161-178.
27. Evans J.G., Chavez-Rueda K.A., Eddaoudi A., Meyer-Bahlburg A., Rawlings D.J., Ehrenstein M.R., et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007, 178:7868-7878.
28. Lenert P., Brummel R., Field E.H., Ashman R.F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005, 25:29-40.
29. Spencer N.F., Daynes R.A. IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5- B cells: possible involvement in age-associated cytokine dysregulation. Int Immunol 1997, 9:745-754.
30. O'Garra A., Howard M. IL-10 production by CD5 B cells. Ann NY Acad Sci 1992, 651:182-199.
31. Jacobi A.M., Huang W., Wang T., Freimuth W., Sanz I., Furie R., et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210.
32. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. HERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
33. Conover W.J., Iman R.L. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 1981, 35:124-129.
34. Carsetti R., Rosado M.M., Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004, 197:179-191.
35. Zaiss M.M., Frey B., Hess A., Zwerina J., Luther J., Nimmerjahn F., et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010, 184:7238-7246.
36. Stephens L.A., Malpass K.H., Anderton S.M. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol 2009, 39:1108-1117.
37. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
38. Wolf S.D., Dittel B.N., Hardardottir F., Janeway C.A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996, 184:2271-2278.
39. Chen F., Shaw M.K., Li J., Lisak R.P., Tse H.Y. Adoptive transfer of myelin basic protein-induced experimental autoimmune encephalomyelitis between SJL and B10.S mice: correlation of priming milieus with susceptibility and resistance phenotypes. J Neuroimmunol 2006, 173:146-154.
40. Reddy J., Illes Z., Zhang X., Encinas J., Pyrdol J., Nicholson L., et al. Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2004, 101:15434-15439.
41. van Zwam M., Huizinga R., Melief M.J., Wierenga-Wolf A.F., van Meurs M., Voerman J.S., et al. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med 2009, 87:273-286.
42. Peterson L.K., Tsunoda I., Fujinami R.S. Role of CD5+ B-1 cells in EAE pathogenesis. Autoimmunity 2008, 41:353-362.
43. Niiro H., Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002, 2:945-956.
44. Zotos D., Coquet J.M., Zhang Y., Light A., D'Costa K., Kallies A., et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 2010, 207:365-378.
45. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
46. Schneider P., Takatsuka H., Wilson A., Mackay F., Tardivel A., Lens S., et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001, 194:1691-1697.
47. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005, 17:282-289.
48. Vora K.A., Wang L.C., Rao S.P., Liu Z.Y., Majeau G.R., Cutler A.H., et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003, 171:547-551.
49. Rahman Z.S., Rao S.P., Kalled S.L., Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003, 198:1157-1169.
50. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006, 18:284-289.
51. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
52. Shulga-Morskaya S., Dobles M., Walsh M.E., Ng L.G., MacKay F., Rao S.P., et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004, 173:2331-2341.
53. Gorelik L., Cutler A.H., Thill G., Miklasz S.D., Shea D.E., Ambrose C., et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004, 172:762-766.
54. Gorelik L., Gilbride K., Dobles M., Kalled S.L., Zandman D., Scott M.L. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003, 198:937-945.
55. Scapini P., Hu Y., Chu C.L., Migone T.S., Defranco A.L., Cassatella M.A., et al. Myeloid cells, BAFF, and IFN-{gamma} establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med 2010, 207:1757-1773.
56. Scapini P., Nardelli B., Nadali G., Calzetti F., Pizzolo G., Montecucco C., et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003, 197:297-302.
57. Lavie F., Miceli-Richard C., Quillard J., Roux S., Leclerc P., Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 2004, 202:496-502.
58. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
59. Zhu X.J., Shi Y., Sun J.Z., Shan N.N., Peng J., Guo C.S., et al. High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 2009, 29:603-610.
60. Andreini I., Getuli C., Pacelli V., Manno R., Ragazzoni E., Nunziata A., et al. Function of the hypothalamo-pituitary-adrenal axis and humoral immune mechanisms during experimental allergic encephalomyelitis in SJL/J mice. Neuroimmunomodulation 2002, 10:9-16.
61. del Rey A., Klusman I., Besedovsky H.O. Cytokines mediate protective stimulation of glucocorticoid output during autoimmunity: involvement of IL-1. Am J Physiol 1998, 275:R1146-R1151.
62. Walters S., Webster K.E., Sutherland A., Gardam S., Groom J., Liuwantara D., et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009, 182:793-801.
63. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
64. Dass S., Vital E.M., Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007, 56:2715-2718.
65. Naismith R.T., Piccio L., Lyons J.A., Lauber J., Tutlam N.T., Parks B.J., et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010, 74:1860-1867.
66. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008, 118:3420-3430.